Finally, combining these results with whole genome sequencing of primary and metastatic PCa, we identified and characterized a non-coding somatic mutation that significantly impacted AR enhancer activity of a critical tumor suppressor. The gene discussed is AR; the disease is posterior cortical atrophy.